Moderna Shares Rise After Investor Day Reveals First In Vivo CAR-T Autoimmune Program

Moderna shares rose after the company used its investor day on June 26 to outline a new autoimmune-disease research push built around in vivo CAR-T, a move that investors viewed as a possible long-term growth catalyst beyond Covid-19 vaccines.

Barron's reported that Moderna stock surged about 13% after the update. WSJ later reported that shares rose after the company disclosed a broader research effort beyond its vaccine business, underscoring how quickly the market reacted to the pipeline news.

Investor Day Update

Moderna said it plans to begin clinical development of mRNA-6007 in 2027. The program is the company’s first in vivo CAR-T effort, meaning it aims to modify T-cells inside the body rather than removing and engineering them outside the body first.

The company said the initial focus will be B-cell-mediated autoimmune diseases, including systemic lupus erythematosus. That puts Moderna into a highly competitive scientific field where researchers are exploring whether cell-therapy concepts can be adapted to autoimmune disease.

The announcement also fits into Moderna’s broader effort to diversify beyond the Covid-19 franchise that made it one of the best-known names in biotech. Coverage of the investor day said the company is advancing oncology and other experimental programs as part of that push.

Why Investors Reacted

The share move suggested investors saw the autoimmune program as more than a routine pipeline update. Moderna is best known for its mRNA vaccine platform, but the investor-day presentation gave the company a new growth narrative centered on a different therapeutic area.

In vivo CAR-T is a notable strategic turn because it attempts to bring a cell-therapy approach into the body itself. That could matter if the platform proves workable, but the program remains early and no clinical data were disclosed in the research record.

The lupus focus also matters because systemic lupus erythematosus is a serious autoimmune disease with a large unmet need. Moderna’s stated target suggests the company is pursuing a B-cell-directed approach in one of the better-known autoimmune settings.

What Comes Next

For now, the key milestones are still ahead. Moderna has not yet started clinical development of mRNA-6007, and the research packet does not include efficacy, safety, or dosing data.

The company also has not publicly answered whether other autoimmune indications will follow lupus. Analysts and investors are likely to watch for the full investor-day materials, webcast details, and any further explanation of the program’s development path.

That leaves the story in a developing phase: the market has already repriced the stock on the announcement, but the scientific and regulatory test is still to come.